RECRUITINGPhase 4INTERVENTIONAL
A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
About This Trial
A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.
Who May Be Eligible (Plain English)
Who May Qualify:
- RR-TB/MDR-TB (resistant to at least isoniazid and rifampicin).
- Poor efficacy of the original treatment regimen or no response to treatment or less than 4 effective drugs.
Who Should NOT Join This Trial:
- Immunosuppression due to co-morbidities, such as immune system disorders, tumors, etc.
- Test confirms poor response to ZOL and IL-2 stimulation.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* RR-TB/MDR-TB (resistant to at least isoniazid and rifampicin).
* Poor efficacy of the original treatment regimen or no response to treatment or less than 4 effective drugs.
Exclusion Criteria:
* Immunosuppression due to co-morbidities, such as immune system disorders, tumors, etc.
* Test confirms poor response to ZOL and IL-2 stimulation.
Treatments Being Tested
DRUG
Vγ2Vδ2 T lymphocyte-based immunotherapy
Intravenous injection of zoledronic acid, followed by a subcutaneous injection recombinant human interleukin. Zoledronic acid was administered 3 times and recombinant human interleukin was administered 10 times for a total of 6 months.
DRUG
Treatment regimens for MDR-TB
Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.
Locations (2)
Shanghai Pulmonary Hospital, Shanghai, China
Shanghai, China
Shanghai Pulmonary Hospital
Shanghai, China